SEC Filing Summary
Issuer: Pieris Pharmaceuticals, Inc. The request metadata names “Pavella Therapeutics, Inc.”; that does not match the issuer identified in this 10-Q.
Reporting period: Three months ended March 31, 2022. Unaudited, consolidated results; comparisons are with the three months ended March 31, 2021.
Business context
Pieris is a clinical-stage biotechnology company developing Anticalin-based therapies, with respiratory and immuno-oncology programs and revenue primarily from licensing and collaboration agreements. It has not generated product-sales revenue.
Financial results and liquidity
| Metric | Q1 2022 | Q1 2021 / prior balance date |
|---|---|---|
| Total revenue | $11.0 million | $15.6 million |
| Operating expenses | $18.4 million | $20.7 million |
| Loss from operations | $7.5 million | $5.1 million |
| Net loss | $5.1 million | $4.2 million |
| Basic and diluted net loss per share | $0.07 | $0.07 |
| Cash, cash equivalents and short-term investments | $100.3 million | $117.8 million cash at Dec. 31, 2021; no short-term investments then |
| Net cash used in operating activities | $22.6 million | $12.1 million |
| Total liabilities | $83.7 million | $102.8 million at Dec. 31, 2021 |
| Accumulated deficit | $262.2 million | $257.1 million at Dec. 31, 2021 |
Revenue fell $4.6 million (about 30%). Customer revenue declined $3.7 million, chiefly because the prior-year period included a $13.0 million AstraZeneca phase 2a milestone; Q1 2022 included revenue from a discontinued AstraZeneca discovery program and Servier and Genentech activity. Collaboration revenue declined $1.0 million, mainly due to a revised estimate of completion for Servier’s PRS-344/S095012 work.
Research and development expense decreased $2.5 million to $14.1 million; general and administrative expense rose $0.2 million to $4.4 million. The company recorded $2.1 million of grant income for PRS-220. Cash used in investing was $16.9 million, largely reflecting purchases of investments; financing provided $6.6 million, primarily from ATM share sales. The company sold 1.8 million shares under its ATM program for $6.7 million gross proceeds.
No borrowing debt is listed on the balance sheet. Lease liabilities were $13.4 million current and $14.4 million in total, including non-current amounts. The filing does not present a gross margin measure; product sales have not begun.
Outlook, developments and risks
- Management expects continued operating losses for several years and says available funds should support operations for at least 12 months from the report’s issuance. This assessment depends on estimates; the company says additional capital may be needed and is not assured on acceptable terms. It may need to defer or limit programs if funding is unavailable.
- PRS-060/AZD1402’s phase 2a asthma study was ongoing. AstraZeneca was reforecasting timelines amid geopolitical and pandemic-related challenges, with greater risk of delay to topline results planned by year-end 2022.
- Pieris reiterated its expectation to report 2023 data for cinrebafusp alfa combined with ramucirumab and paclitaxel in HER2-high gastric cancer. It revised the expected timing for data from the tucatinib combination in HER2-low gastric cancer to 2023, citing slower-than-anticipated enrollment.
- PRS-220 remained in clinical-enabling development, with a phase 1 study in healthy volunteers planned for 2022. A Bavarian grant of €14.2 million (approximately $17.0 million) supports qualifying development costs through August 2023.
- The first patient in the PRS-344/S095012 phase 1/2 study had been dosed in November 2021; U.S. regulatory approval was received in Q1 2022. Boston Pharmaceuticals was expected to file an IND for licensed PRS-342/BOS-342 within 12 months.
- One AstraZeneca discovery program was discontinued in January 2022 after the target could not be validated. Collaboration milestones and royalties are contingent on development and commercial success; most research and development milestone revenue remains constrained until a significant reversal is no longer considered probable.
- Material risks include clinical and regulatory uncertainty, dependence on collaborators and third parties, ongoing cash needs, possible dilution from future equity financing, foreign-exchange exposure, and potential trial delays associated with COVID-19 and geopolitical conditions. No material pending legal proceedings or material changes to the prior annual report’s risk factors were reported.
Important facts for investors to verify
- Confirm the issuer identity: the filing is for Pieris Pharmaceuticals, Inc., not the company named in the request metadata.
- Track cash burn and financing capacity against management’s stated minimum 12-month runway, including subsequent ATM activity or other capital raises.
- Check updated timelines, enrollment and results for the AstraZeneca asthma study and both cinrebafusp alfa phase 2 arms.
- Review collaboration revenue, deferred revenue balances and milestone constraints, which can cause reported quarterly revenue to vary materially.
- Assess clinical, manufacturing and regulatory progress across PRS-220, PRS-344/S095012 and partnered programs, along with the effect of any program discontinuations.